Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Liabilities and Shareholders Equity (2020 - 2021)

Design Therapeutics' Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $400.4 million for Q3 2021.

  • For Q3 2021, Liabilities and Shareholders Equity changed N/A year-over-year to $400.4 million; the TTM value through Dec 2021 reached $1.2 billion, up 3233.75%, while the annual FY2020 figure was $36.5 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q3 2021 was $400.4 million at Design Therapeutics, down from $405.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $411.9 million in Q1 2021 and bottomed at $36.5 million in Q4 2020.